62 publications
| Name | Date | Type | Actions |
|---|---|---|---|
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
26/01/2017 | Public releases | |
2017 sales: €352.2 million 7.6% like-for-like growth in essentials products The Vetoquinol Group posted sales of €352.2 million for the 2017 financial year, up 1.0% like-forlike. After a negative currency impact of 0.5%, mainly linked to the US and Canadian dollars, reported growth amounted to 0.5%. |
23/01/2018 | Public releases | |
2015 results sales of reference products up 9.4% ebit up 10.3% At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements. |
21/03/2016 | Public releases | |
September 2016 year-to-date sales: €257.5 million a 4.8% organic growth Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. |
18/10/2016 | Public releases | |
Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction. |
16/04/2014 | Public releases | |
Q1 2018 sales: €87.6M like-for-like growth up 5.6%, 0.4% as reported growth of essentials products: up 6.8% as reported Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee. |
12/04/2018 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases | |
2023 HALF-YEAR RESULTS Sales: €256m (-5.4% as reported) |
07/09/2023 | Public releases | |
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
23/03/2023 | Public releases | |
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
15/09/2022 | Public releases |